Key Takeaways
- A legitimate hospital, a filed research institution, a registered trial and an activated recruiting site are four different facts. Verify all four.
- Use stable identifiers: hospital licence details, trial registry number, sponsor protocol number, ethics approval, current consent version and named principal investigator.
- A registry record improves transparency but is not regulatory approval, ethics approval, proof of current recruitment or proof that the intervention works [9].
- Match the exact campus and department. A famous hospital group may have several campuses, and only one may participate in the protocol.
- Recruiters, travel agents and coordinators may arrange contact; they cannot independently confirm eligibility, obtain valid consent or promise allocation and benefit.
Content
“This is a research hospital” is not enough to establish that a proposed study is genuine. The hospital may be real but not involved in the named trial. The trial may be registered but closed at that site. A physician may work at the hospital but not be the protocol’s investigator. A commercial recruiter may copy a genuine registry entry and then sell access to a different intervention.
Verification works best as an identity-matching exercise. Collect the claims first; then see whether independent records join them into one consistent chain.
Build a one-page identity sheet
Before sending a passport or complete medical record, request:
- full legal name of the hospital in Chinese and English;
- exact campus, building, department and official switchboard;
- principal investigator’s Chinese name, title and hospital contact;
- trial public title and scientific title;
- Chinese drug-trial registration number, ChiCTR/other registry number and sponsor protocol number;
- sponsor and, if applicable, contract research organisation;
- investigational product/device name, formulation/model and development phase;
- disease, stage, biomarker and treatment-line criteria;
- current recruitment status at this site;
- ethics committee name, approval number/date and current consent version;
- which research costs, standard-care costs and travel costs each party pays.
Save the original invitation, webpage, messages and payment instructions. A changing trial title or refusal to provide identifiers is itself useful evidence.
Check 1: Is the medical institution legally registered?
Search the hospital’s Chinese legal name, address, registration details and authorised clinical services through National Health Commission or local health-authority records. The NHC data-query portal links to hospital practice-registration information and professional queries [1]. Verify the campus rather than relying on a hospital-group logo.
Then call a telephone number obtained independently from the hospital’s official site or government record. Ask the operator to connect you to the clinical-trial office/GCP office or named department. Do not use only the number supplied by a social-media account.
This confirms an institution exists. It does not yet confirm a trial.
Check 2: Is the institution filed for the relevant research category?
China changed drug clinical-trial institutions from accreditation to record-filing management in December 2019 [4]. Device-trial institutions also use filing; the official service describes searchable filed information such as institution address, relevant specialties and principal investigators [5].
Check whether the institution and relevant specialty are filed for the type of study. Do not treat “GCP centre” as a universal licence covering every department, device and intervention. Filing is an institutional condition, not evidence that a specific protocol has ethics approval or is recruiting.
Non-registration research—observational studies, investigator-initiated interventions, use of samples/data or behavioural research—may follow a different regulatory path. It still needs an accountable institution and appropriate ethics review under China’s 2023 measures for life-science and medical research involving humans [6]. Ask the research office which category applies and which authority oversees it.
Check 3: Is the trial publicly registered under the same identity?
For drug-registration trials in China, search the NMPA/CDE Drug Clinical Trial Registration and Information Disclosure Platform. The official service explains that trials conducted in China under the relevant drug process are registered and publicly disclosed, with subsequent updates submitted [2]. The public record can show a CTR number, product, indication, sponsor, protocol number, version, design, eligibility, sites and contacts [3].
For other human studies, search ChiCTR, ClinicalTrials.gov or another WHO primary/ICMJE-accepted registry as appropriate. WHO lists ChiCTR as a primary registry [10]. Search by protocol number and product as well as title; translations and abbreviations can vary.
Match at least:
Field · What must agree
Identifiers · registry ID and sponsor protocol number
Intervention · exact drug/cell/device, route or model
Population · cancer/disease, stage, prior treatment and biomarker
Design · phase, randomisation, masking, comparator and cohort
Sponsor · legal organisation, not only a brand name
Site · exact hospital/campus and principal investigator
Status · overall study and local site recruitment
Dates/version · registry update, protocol and consent currently used
WHO’s minimum trial-registration dataset includes the primary registry number, registration date, sponsor-issued identifiers, sponsor, interventions, eligibility, outcomes and recruitment information [9]. A complete-looking record can still be stale; note its last update.
Check 4: Is this exact site activated and recruiting now?
“Recruiting” on a multinational record may describe the study overall, not every site. A listed site may be awaiting ethics approval, contract, product shipment or initiation; it may have met its quota or paused screening.
Ask the hospital’s research office to confirm in writing:
- the site is initiated/activated under the specified protocol and current version;
- local ethics approval remains valid;
- the named principal investigator is responsible at this campus;
- the cohort relevant to the patient is open;
- the first clinical contact is an authorised study-team member;
- screening procedures will occur only after the required consent.
Do not ask for confidential enrolment data. A simple confirmation of the protocol, site and open cohort is enough.
Regulatory permission, ethics approval and registration answer different questions
- Regulatory permission addresses whether the drug/device development pathway may proceed under the applicable rules.
- Institution filing and site activation address whether this organisation and team can conduct the protocol.
- Ethics review addresses participant rights, risk–benefit, consent, privacy, compensation and ongoing oversight.
- Public registration makes a defined dataset visible and traceable.
None substitutes for the others. A registry is not a government recommendation. Ethics approval is not evidence of efficacy. Institutional filing is not permission to advertise guaranteed access.
China’s 2023 ethics measures place protection of participant rights, health and dignity at the centre and cover research using people, biological samples, health records and other human data [6]. Ask for the ethics committee’s full name and approval identifier, but the hospital may appropriately decline to hand an outsider a complete confidential committee file before screening.
Check the consent document at the version level
The consent title, protocol number and intervention must match the registry and invitation. The footer should identify the version/date. Verify who is the sponsor, what is experimental, randomisation or placebo, foreseeable risks, alternatives, injury treatment/compensation, privacy and data transfer, sample storage, pregnancy rules, costs, withdrawal and contacts.
The currently effective Chinese drug GCP at this review date is the 2020 version; it makes participant rights and safety the primary consideration and treats ethics review and informed consent as core protections [7]. A revised GCP was published in 2026 and is scheduled to take effect on 1 September 2026, when the 2020 version will be repealed [8]. A trial spanning the transition should explain how it implements the applicable requirements.
Consent is a discussion, not a signature service. Translation must allow the patient to understand the actual document. An interpreter or coordinator should not answer clinical questions in the investigator’s place.
Separate the people and their incentives
Map each person:
Role · Legitimate function · What to verify
Principal investigator · medical and protocol responsibility at the site · hospital appointment, filed specialty, protocol listing
Sub-investigator/research nurse · screening, visits, data and safety tasks · study-team identity and hospital contact
Sponsor · owns/initiates and funds the study · legal name and registry match
CRO · performs delegated trial operations · written relationship; not the sponsor unless stated
Site management organisation · operational support · hospital authorisation and scope
Recruitment/travel agency · referral, translation or logistics · fees, data handling, conflicts; no clinical promises
A referral payment does not automatically invalidate a study, but hidden commission can distort advice. Ask who pays the recruiter and whether the hospital has authorised it. Trial participation should not be sold as a reservation, membership or “special channel.”
Verify the intervention that will actually be administered
Marketing may use a platform name while the protocol uses a different product. Check exact generic/code name, manufacturer, batch accountability, route, dose/cohort and whether the intervention is investigational, approved for another use or standard care used as a comparator.
For cell or gene studies, confirm product identity, autologous/allogeneic source, manufacturing release, conditioning and long-term follow-up. For devices, confirm model and whether the study evaluates a prototype, software version, procedure or new indication. The consent, pharmacy/device accountability records and registry should tell the same story.
Payment patterns that require escalation
Clarify research-paid procedures, standard clinical care, travel/lodging, interpreter, companion, complication care and screening-failure costs. Payment should go through the hospital or disclosed contractual channel with an invoice—not to an investigator’s or recruiter’s personal account.
Pause when asked to pay for:
- a guaranteed trial place or randomisation arm;
- an unlabelled investigational product outside hospital pharmacy/accountability;
- “ethics approval acceleration”;
- a large non-refundable deposit before professional record review;
- undisclosed brokerage or success fees;
- tests unrelated to the protocol with no clinical explanation.
Some trials reimburse reasonable expenses or compensate time; that does not mean every cost is free. The written consent and budget explanation control.
Cross-border checks before travel
Obtain a written pre-screen result from an authorised clinician, but understand that it is not enrolment. Ask which eligibility tests must be repeated at the site, acceptable laboratories/methods, screening window, washout, contraception, infectious-disease tests, tissue shipment and whether a local companion is required.
Plan for screen failure. Confirm visa support is accurate, who pays return travel, whether standard treatment continues during screening, and how urgent care works. Before sharing full records, verify the receiving hospital account, purpose, retention, cross-border transfer and whether samples/genetic data need additional consent or approval.
Use a stop rule for unresolved mismatches
Do not rationalise away a mismatch because the treatment is urgent. Stop and seek an independent answer if:
- the CTR/registry ID resolves to a different disease or product;
- the hospital is not listed and cannot confirm site activation;
- the investigator name or department cannot be verified;
- the protocol/consent number changes without an amendment explanation;
- recruitment continues after the public record says terminated for safety;
- the recruiter blocks direct hospital contact;
- payment instructions conflict with hospital finance procedures.
Record the discrepancy and ask the hospital research office, sponsor contact and registry contact separately. Three consistent independent answers are stronger than repeated reassurance from one salesperson.
Medical disclaimer: Verification establishes identity and governance, not personal eligibility or likely benefit. A qualified study investigator must assess the complete medical record, and the patient should discuss alternatives with an independent treating clinician.
FAQ
Does a registered trial mean the government approved the treatment?
No. Registration is public disclosure. Regulatory permission, ethics approval and evidence of benefit are separate matters.
If the hospital is a filed GCP institution, is every trial there legitimate?
No. Confirm the relevant specialty, exact protocol, local ethics approval, principal investigator, site activation and current cohort status.
Why is the hospital not shown on a registry record?
It may not be a site, may not yet be activated, or the public record may be incomplete or stale. Do not travel until the hospital research office and sponsor confirm the exact site in writing.
Can a recruiter guarantee that I will receive the experimental treatment?
No. Eligibility is determined by the authorised study team, and randomised trials may assign a comparator or placebo according to the protocol.
What is the minimum information I should have before sending records?
Hospital legal name and campus, investigator, registry and protocol numbers, sponsor, intervention, disease/cohort, official hospital contact and a secure authorised submission route.
Sources
- National Health Commission of China — Health Institution and Professional Data Queries
- National Medical Products Administration — Drug Clinical Trial Registration Service Guide
- NMPA/CDE — Drug Clinical Trial Registration and Information Disclosure Platform
- NMPA and NHC — Record-Filing Management of Drug Clinical Trial Institutions
- NMPA — Medical Device Clinical Trial Institution Filing Service
- National Health Commission of China — Ethical Review Measures for Life-Science and Medical Research Involving Humans
- China Drug Good Clinical Practice (2020, effective at review date)
- China Drug Good Clinical Practice (2026 revision, effective 1 September 2026)
- World Health Organization — Trial Registration Data Set
- World Health Organization — Primary Registries, Including ChiCTR
Image Review
- Decision: Approved after editorial review; copied as hero-reviewed.png.
- Editorial note: The checklist, magnifier, safety shield, identity badge, international patient and hospital reception make verification the identifiable action. It remains conceptual: the person at the desk may be a coordinator, not an investigator or ethics reviewer, and the image does not prove any hospital or trial is authorised.